JP2009510171A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009510171A5 JP2009510171A5 JP2008534665A JP2008534665A JP2009510171A5 JP 2009510171 A5 JP2009510171 A5 JP 2009510171A5 JP 2008534665 A JP2008534665 A JP 2008534665A JP 2008534665 A JP2008534665 A JP 2008534665A JP 2009510171 A5 JP2009510171 A5 JP 2009510171A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- leukemia
- composition according
- isoindol
- dione
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- GOTYRUGSSMKFNF-UHFFFAOYSA-N Lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 11
- 206010024324 Leukaemias Diseases 0.000 claims 9
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 claims 7
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 claims 7
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims 4
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 108010001645 Rituximab Proteins 0.000 claims 2
- 201000005510 acute lymphocytic leukemia Diseases 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 201000006934 chronic myeloid leukemia Diseases 0.000 claims 2
- 229960004641 rituximab Drugs 0.000 claims 2
- 108020001267 IL3 Proteins 0.000 claims 1
- 102100018758 IL3 Human genes 0.000 claims 1
- -1 antibiotic Substances 0.000 claims 1
- 108090001123 antibodies Proteins 0.000 claims 1
- 102000004965 antibodies Human genes 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000003115 biocidal Effects 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 1
- 229960000390 fludarabine Drugs 0.000 claims 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical group C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 229940121354 immunomodulators Drugs 0.000 claims 1
- 230000001861 immunosuppresant Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 230000000306 recurrent Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/244,117 | 2005-10-04 | ||
| US11/244,117 US7393862B2 (en) | 2002-05-17 | 2005-10-04 | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| PCT/US2006/038844 WO2007041637A2 (en) | 2005-10-04 | 2006-10-03 | Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013005399A Division JP2013091659A (ja) | 2005-10-04 | 2013-01-16 | 特定の白血病の治療のために３−（４−アミノ−１−オキソ−１，３−ジヒドロ−イソインドール−２−イル）−ピペリジン−２，６−ジオンを使用する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009510171A JP2009510171A (ja) | 2009-03-12 |
| JP2009510171A5 true JP2009510171A5 (US20070167479A1-20070719-C00034.png) | 2009-08-27 |
| JP5916977B2 JP5916977B2 (ja) | 2016-05-11 |
Family
ID=37603038
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008534665A Active JP5916977B2 (ja) | 2005-10-04 | 2006-10-03 | 特定の白血病の治療のために３−（４−アミノ−１−オキソ−１，３−ジヒドロ−イソインドール−２−イル）−ピペリジン−２，６−ジオンを使用する方法 |
| JP2013005399A Pending JP2013091659A (ja) | 2005-10-04 | 2013-01-16 | 特定の白血病の治療のために３−（４−アミノ−１−オキソ−１，３−ジヒドロ−イソインドール−２−イル）−ピペリジン−２，６−ジオンを使用する方法 |
| JP2014188693A Pending JP2015044811A (ja) | 2005-10-04 | 2014-09-17 | 特定の白血病の治療のために３−（４−アミノ−１−オキソ−１，３−ジヒドロ−イソインドール−２−イル）−ピペリジン−２，６−ジオンを使用する方法 |
| JP2017136968A Pending JP2017222686A (ja) | 2005-10-04 | 2017-07-13 | 特定の白血病の治療のために３−（４−アミノ−１−オキソ−１，３−ジヒドロ−イソインドール−２−イル）−ピペリジン−２，６−ジオンを使用する方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013005399A Pending JP2013091659A (ja) | 2005-10-04 | 2013-01-16 | 特定の白血病の治療のために３−（４−アミノ−１−オキソ−１，３−ジヒドロ−イソインドール−２−イル）−ピペリジン−２，６−ジオンを使用する方法 |
| JP2014188693A Pending JP2015044811A (ja) | 2005-10-04 | 2014-09-17 | 特定の白血病の治療のために３−（４−アミノ−１−オキソ−１，３−ジヒドロ−イソインドール−２−イル）−ピペリジン−２，６−ジオンを使用する方法 |
| JP2017136968A Pending JP2017222686A (ja) | 2005-10-04 | 2017-07-13 | 特定の白血病の治療のために３−（４−アミノ−１−オキソ−１，３−ジヒドロ−イソインドール−２−イル）−ピペリジン−２，６−ジオンを使用する方法 |
Country Status (18)
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE48890E1 (en) | 2002-05-17 | 2022-01-11 | Celgene Corporation | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation |
| US7393862B2 (en) * | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US11116782B2 (en) | 2002-10-15 | 2021-09-14 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| US20050100529A1 (en) * | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
| MX2008002765A (es) | 2005-08-31 | 2008-04-07 | Celgene Corp | Compuestos de isoindol-imida y composiciones que la comprenden y metodos para usar los mismos. |
| WO2008019379A2 (en) * | 2006-08-07 | 2008-02-14 | Pdl Biopharma, Inc. | Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells |
| US8877780B2 (en) | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
| ATE555104T1 (de) | 2006-09-26 | 2012-05-15 | Celgene Corp | 5-substituierte chinazolinon-derivate als antitumorverbindungen |
| US20090175869A1 (en) * | 2007-05-31 | 2009-07-09 | Ascenta Therapeutics, Inc. | Pulsatile Dosing of Gossypol for Treatment of Disease |
| NZ584425A (en) | 2007-09-26 | 2012-03-30 | Celgene Corp | 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same |
| US20100311683A1 (en) * | 2007-11-01 | 2010-12-09 | Beach C L | Cytidine analogs for treatment of myelodysplastic syndromes |
| US20100310563A1 (en) * | 2007-11-30 | 2010-12-09 | Bumm Thomas G P | Methods for treating induced cellular proliferative disorders |
| US20090148853A1 (en) * | 2007-12-07 | 2009-06-11 | Schafer Peter H | Biomarkers for predicting the sensitivity of cells to immunomodulatory compounds during treatment of non-hodgkin's lymphoma |
| EP2262768A4 (en) * | 2008-03-11 | 2011-03-23 | Reddys Lab Ltd Dr | PREPARATION OF LENALIDOMIDE |
| WO2009139880A1 (en) * | 2008-05-13 | 2009-11-19 | Celgene Corporation | Thioxoisoindoline compounds and compositions and methods of using the same |
| PT2358697E (pt) | 2008-10-29 | 2016-02-03 | Celgene Corp | Compostos de isoindolina para utilização no tratamento do cancro |
| US20120046315A1 (en) * | 2008-11-14 | 2012-02-23 | Katrin Rimkus | Intermediate and oral administrative formats containing lenalidomide |
| WO2010093434A1 (en) | 2009-02-11 | 2010-08-19 | Celgene Corporation | Isotopologues of lenalidomide |
| MX342330B (es) | 2009-05-19 | 2016-09-26 | Celgene Corp | Formulaciones de 4-amino-2-(2, 6-dioxopiperidin-3-il) isoindolin-1, 3-diona. |
| WO2010137547A1 (ja) | 2009-05-25 | 2010-12-02 | 国立大学法人東京工業大学 | 中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物 |
| MX2012005849A (es) * | 2009-11-24 | 2012-08-23 | Celgene Corp | Compuestos inmunomoduladores para la restauracion de la sensibilidad a vitamina d en celulas tumorales resistentes a vitamina d. |
| CA2783616A1 (en) | 2009-12-22 | 2011-06-30 | Celgene Corporation | (methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutical uses |
| US9226913B2 (en) | 2010-01-05 | 2016-01-05 | Celgene Corporation | Methods of treating cancer using a combination of an immunomodulatory compound and an artemisinin or a derivative thereof |
| NZ601289A (en) | 2010-02-11 | 2014-10-31 | Celgene Corp | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| AU2011224166B2 (en) * | 2010-03-12 | 2014-08-21 | Celgene Corporation | Methods for the treatment of non-Hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor |
| US9499461B2 (en) * | 2010-08-27 | 2016-11-22 | Neonc Technologies, Inc. | Pharmaceutical compositions comprising POH derivatives |
| US9913838B2 (en) | 2010-08-27 | 2018-03-13 | Neonc Technologies, Inc. | Methods of treating cancer using compositions comprising perillyl alcohol derivative |
| WO2012079075A1 (en) | 2010-12-10 | 2012-06-14 | Concert Pharmaceuticals, Inc. | Deuterated phthalimide derivatives |
| EP2663549B1 (en) | 2011-01-10 | 2018-03-14 | Celgene Corporation | Phenethylsulfone isoindoline derivatives as inhibitors of pde 4 and/or cytokines |
| WO2012125438A1 (en) | 2011-03-11 | 2012-09-20 | Celgene Corporation | Solid forms of 3-(5-amino-2methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses |
| ES2659205T3 (es) | 2011-03-11 | 2018-03-14 | Celgene Corporation | Uso de 3-(5-amino-2-metil-4-oxoquinazolin-3(4H)-il)piperidin-2,6-diona en el tratamiento de enfermedades inflamatorias y relacionadas con el sistema inmune |
| EP2699091B1 (en) | 2011-03-28 | 2017-06-21 | DeuteRx, LLC | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
| CA2834535A1 (en) | 2011-04-29 | 2012-11-01 | Celgene Corporation | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
| WO2012177678A2 (en) | 2011-06-22 | 2012-12-27 | Celgene Corporation | Isotopologues of pomalidomide |
| CA2848493A1 (en) | 2011-09-14 | 2013-03-21 | Celgene Corporation | Formulations of cyclopropanecarboxylic acid {2-[(1s)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amide |
| CN103890667B (zh) | 2011-10-21 | 2017-02-15 | 谷歌公司 | 用户友好、网络连接的学习型恒温器及相关系统和方法 |
| CA2861594A1 (en) | 2011-12-27 | 2013-07-04 | Celgene Corporation | Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetylaminoisoindoline-1,3-dione |
| WO2013130849A1 (en) | 2012-02-29 | 2013-09-06 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
| WO2013159026A1 (en) | 2012-04-20 | 2013-10-24 | Concert Pharmaceuticals, Inc. | Deuterated rigosertib |
| EP2867671B1 (en) | 2012-06-29 | 2018-10-24 | Celgene Corporation | Methods for determining drug efficacy using cereblon-associated proteins |
| WO2014007303A1 (ja) * | 2012-07-06 | 2014-01-09 | 学校法人 聖マリアンナ医科大学 | Ｈｔｌｖ－１関連脊髄症患者の治療方法および治療剤 |
| IL288506B2 (en) | 2012-08-09 | 2023-09-01 | Celgene Corp | Methods for treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoisoindolin-2-yl)piperidine-2,6-dione |
| EP2864427B1 (en) * | 2012-08-09 | 2021-10-06 | Nutrition & Biosciences USA 2, LLC | Coating composition with biocide |
| IN2015DN00885A (US20070167479A1-20070719-C00034.png) | 2012-08-09 | 2015-06-12 | Celgene Corp | |
| US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
| EP2922838B1 (en) | 2012-10-22 | 2018-03-14 | Concert Pharmaceuticals Inc. | Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2-yl)(piperidine-3,4,4,5,5-d5)-2,6-dione} . |
| WO2014110322A2 (en) | 2013-01-11 | 2014-07-17 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
| WO2014110558A1 (en) | 2013-01-14 | 2014-07-17 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
| EP2764866A1 (en) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
| EP2815749A1 (en) | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern |
| CN103610658B (zh) * | 2013-11-15 | 2017-04-12 | 广州帝奇医药技术有限公司 | 一种免疫调节剂缓释剂及其制备方法 |
| EP3827836A1 (en) | 2014-06-27 | 2021-06-02 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases |
| US9499514B2 (en) * | 2014-07-11 | 2016-11-22 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
| FI3182996T3 (fi) | 2014-08-22 | 2023-03-28 | Celgene Corp | Menetelmiä multippelin myelooman hoitamiseksi immuunivastetta muuntavilla yhdisteillä yhdistelmässä vasta-aineiden kanssa |
| WO2016201337A1 (en) * | 2015-06-12 | 2016-12-15 | Immungene, Inc. | Engineered antibody-interferon fusion molecules for the treatment of glucose-regulated protein 94 (grp94) expressing cancers |
| WO2016210262A1 (en) | 2015-06-26 | 2016-12-29 | Celgene Corporation | Methods for the treatment of kaposi's sarcoma or kshv-induced lymphoma using immunomodulatory compounds, and uses of biomarkers |
| KR101885361B1 (ko) | 2015-08-17 | 2018-08-06 | 쿠라 온콜로지, 인크. | 파르네실전달효소 억제제를 이용하여 암환자를 치료하는 방법 |
| BR112018012914B1 (pt) | 2015-12-22 | 2023-04-18 | SHY Therapeutics LLC | Composto, uso de um composto e composição farmacêutica |
| US10830762B2 (en) | 2015-12-28 | 2020-11-10 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases |
| WO2018013689A1 (en) | 2016-07-13 | 2018-01-18 | Celgene Corporation | Solid dispersions and solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, method of preparation and use thereof |
| WO2018013693A1 (en) | 2016-07-13 | 2018-01-18 | Celgene Corporation | Solid dispersions and cocrystals comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione compositions and methods of use thereof |
| US20180238886A1 (en) * | 2017-01-31 | 2018-08-23 | Celgene Corporation | Methods for treating hematological cancer and the use of biomarkers as a predictor for responsiveness to treatment compounds |
| US10093647B1 (en) | 2017-05-26 | 2018-10-09 | Celgene Corporation | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate, compositions and methods of use thereof |
| US10093648B1 (en) | 2017-09-22 | 2018-10-09 | Celgene Corporation | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof |
| US10093649B1 (en) | 2017-09-22 | 2018-10-09 | Celgene Corporation | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof |
| WO2019113269A1 (en) | 2017-12-08 | 2019-06-13 | Kura Oncology, Inc. | Methods of treating cancer patients with farnesyltransferase inhibitors |
| WO2019138424A1 (en) * | 2018-01-11 | 2019-07-18 | Natco Pharma Limited | Stable pharmaceutical compositions comprising lenalidomide |
| CA3090291C (en) | 2018-02-07 | 2023-10-17 | Lovelace Biomedical Research Institute | Inhalable dry powder cytidine analogue composition and method of use as a treatment for cancer |
| US20220142983A1 (en) | 2019-03-01 | 2022-05-12 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
| US20220143006A1 (en) | 2019-03-15 | 2022-05-12 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
| BR112022010537A2 (pt) | 2019-12-02 | 2022-08-16 | Celgene Corp | Terapia para o tratamento do câncer |
| AR129053A1 (es) | 2022-04-14 | 2024-07-10 | Bristol Myers Squibb Co | Nuevos compuestos gspt1 y métodos de uso de los nuevos compuestos |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) * | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) * | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) * | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) * | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5391485A (en) * | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
| JPS63500636A (ja) * | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| US4810643A (en) * | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| US5073543A (en) * | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) * | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) * | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5733566A (en) * | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| AU1531492A (en) | 1991-02-14 | 1992-09-15 | Rockefeller University, The | Method for controlling abnormal concentration tnf alpha in human tissues |
| US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5360352A (en) * | 1992-12-24 | 1994-11-01 | The Whitaker Corporation | Wire retainer for current mode coupler |
| US5591767A (en) * | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6228879B1 (en) * | 1997-10-16 | 2001-05-08 | The Children's Medical Center | Methods and compositions for inhibition of angiogenesis |
| US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| US8143283B1 (en) * | 1993-03-01 | 2012-03-27 | The Children's Medical Center Corporation | Methods for treating blood-born tumors with thalidomide |
| US6114355A (en) * | 1993-03-01 | 2000-09-05 | D'amato; Robert | Methods and compositions for inhibition of angiogenesis |
| US20010056114A1 (en) * | 2000-11-01 | 2001-12-27 | D'amato Robert | Methods for the inhibition of angiogenesis with 3-amino thalidomide |
| GB9515279D0 (en) * | 1995-07-25 | 1995-09-20 | Norsk Hydro As | Improved therapeutic agents |
| US5698579A (en) * | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
| US6077822A (en) * | 1993-09-14 | 2000-06-20 | Dumex-Alpharma A/S | Drug salts |
| IT1270594B (it) * | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| MX9706449A (es) * | 1995-02-28 | 1997-11-29 | Hoechst Marion Roussel Inc | Composicion farmaceutica para compuestos de piperidinalcanol. |
| US5731325A (en) * | 1995-06-06 | 1998-03-24 | Andrulis Pharmaceuticals Corp. | Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents |
| US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| US5798368A (en) * | 1996-08-22 | 1998-08-25 | Celgene Corporation | Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels |
| US6281230B1 (en) * | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| HU228769B1 (en) * | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| CA2624949C (en) | 1996-07-24 | 2011-02-15 | Celgene Corporation | Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing tnf.alpha. levels |
| DK0918746T3 (da) * | 1996-08-12 | 2003-08-04 | Celgene Corp | Immunterapeutiske midler og deres anvendelse til reduktion af cytokinniveauer |
| DE69734290T2 (de) * | 1996-11-05 | 2006-07-06 | The Children's Medical Center Corp., Boston | Mittel zur hemmung von angiogenese enthaltend thalodomid und einen nsaid |
| HUP9903330A2 (hu) * | 1996-11-19 | 2000-03-28 | Amgen Inc. | Gyulladásgátló hatású, aril- és heteroaril csoporttal szubsztituált kondenzált pirrolszármazékok, valamint ezeket tartalmazó gyógyászati készítmények |
| US5874448A (en) * | 1997-11-18 | 1999-02-23 | Celgene Corporation | Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels |
| US5955476A (en) * | 1997-11-18 | 1999-09-21 | Celgene Corporation | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels |
| US5919813C1 (en) * | 1998-03-13 | 2002-01-29 | Univ Johns Hopkins Med | Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy |
| EP1357120A1 (en) * | 1998-03-16 | 2003-10-29 | Celgene Corporation | 2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines |
| US6673828B1 (en) | 1998-05-11 | 2004-01-06 | Children's Medical Center Corporation | Analogs of 2-Phthalimidinoglutaric acid |
| US6020358A (en) * | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
| US20030013739A1 (en) * | 1998-12-23 | 2003-01-16 | Pharmacia Corporation | Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia |
| CZ20013338A3 (cs) * | 1999-03-18 | 2002-03-13 | Celgene Corporation | Substituované 1-oxo-a l,3-dioxoisoindoliny a jejich pouľití ve farmaceutických prostředcích pro sníľení koncentrací zánětlivých cytokinů |
| US6228756B1 (en) * | 1999-08-10 | 2001-05-08 | United Microelectronics Corp. | Method of manufacturing inter-metal dielectric layer |
| US7182953B2 (en) * | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
| US6326388B1 (en) * | 1999-12-21 | 2001-12-04 | Celgene Corporation | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level |
| CA2319872C (en) * | 2000-02-02 | 2012-06-19 | Chun-Ying Huang | Pharmaceutical composition for the treatment of hepatocellular carcinoma |
| SI21172A (sl) | 2000-03-17 | 2003-10-31 | Cell Therapeutics, Inc. | Konjugati poliglutaminska kislina-kamptotecin in postopki za pripravo |
| US20020022627A1 (en) * | 2000-03-31 | 2002-02-21 | Dannenberg Andrew J. | Inhibition of cyclooxygenase-2activity |
| BR0110877A (pt) * | 2000-05-15 | 2003-03-11 | Celgene Corp | Métodos de tratamento de câncer primário, de aumento da dosagem de um inibidor de topoisomerase, de redução ou prevenção de um efeito adverso associado com quimioterapia e com terapia de radiação, de aumento da eficácia terapêutica de um inibidor de topoisomerase, e de proteção de um paciente canceroso dos efeitos adversos associados com a administração de uma droga anti-câncer, composição farmacêutica, forma de dosagem, e, kit para uso no tratamento de câncer |
| AU2001268363B2 (en) * | 2000-06-20 | 2006-08-17 | Biogen Idec Inc. | Treatment of B cell associated diseases |
| AU2001280161A1 (en) | 2000-08-24 | 2002-03-04 | Kirin Beer Kabushiki Kaisha | C-mpl ligand-containing medicinal compositions for increasing platelets and erythrocytes |
| US6458810B1 (en) * | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
| WO2002064083A2 (en) * | 2000-11-30 | 2002-08-22 | The Children's Medical Center Corporation | Synthesis of 3-amino-thalidomide and its enantiomers |
| US20020128228A1 (en) * | 2000-12-01 | 2002-09-12 | Wen-Jen Hwu | Compositions and methods for the treatment of cancer |
| ES2522890T3 (es) | 2000-12-06 | 2014-11-19 | Anthrogenesis Corporation | Método para recolectar células troncales placentarias |
| US20030032179A1 (en) | 2000-12-06 | 2003-02-13 | Hariri Robert J. | Post-partum mammalian placenta, its use and placental stem cells therefrom |
| US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| US7091353B2 (en) * | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
| WO2002068414A2 (en) * | 2001-02-27 | 2002-09-06 | The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Analogs of thalidomide as potential angiogenesis inhibitors |
| US6734177B2 (en) | 2001-04-17 | 2004-05-11 | Novartis Ag | Certain salts of discodermolide acid, pharmaceutical compositions containing them and their use in treating tumors |
| US7361341B2 (en) * | 2001-05-25 | 2008-04-22 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to trail receptors |
| JP4494013B2 (ja) | 2001-08-06 | 2010-06-30 | ザ チルドレンズ メディカル センター コーポレイション | 窒素置換サリドマイド誘導体の合成及び抗腫瘍活性 |
| EP1443927B1 (en) * | 2001-11-07 | 2007-01-10 | Millennium Pharmaceuticals, Inc. | Carboline derivatives as inhibitors of ikb in the treatment of multiple myeloma |
| AU2003217961B2 (en) * | 2002-03-08 | 2008-02-28 | Signal Pharmaceuticals, Llc | Combination therapy for treating, preventing or managing proliferative disorders and cancers |
| US20050148034A1 (en) | 2002-04-12 | 2005-07-07 | Hariri Robert J. | Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds |
| US7498171B2 (en) * | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| CN102429908A (zh) * | 2002-05-17 | 2012-05-02 | 细胞基因公司 | 用于治疗和控制多发性骨髓瘤的方法及组合物 |
| US7323479B2 (en) * | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| US7393862B2 (en) * | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| CA2487070A1 (en) | 2002-05-24 | 2003-12-04 | Sicor Inc. | Aqueous fludarabine phosphate composition |
| US8404716B2 (en) * | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| US7189740B2 (en) * | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| US20040091455A1 (en) * | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| US7563810B2 (en) * | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| US7189746B2 (en) * | 2002-11-08 | 2007-03-13 | Gliamed, Inc. | Methods for promoting wound healing |
| MXPA05009102A (es) * | 2003-02-28 | 2006-05-31 | Bayer Pharmaceuticals Corp | Derivados de piridina sustituida utiles en el tratamiento del cancer y otros trastornos. |
| CL2004001004A1 (es) * | 2003-05-19 | 2005-03-18 | Upjohn Co | Combinacion farmaceutica que comprende irinotecan y revimid para tratar el mieloma multiple. |
| US6733566B1 (en) * | 2003-06-09 | 2004-05-11 | Alcoa Inc. | Petroleum coke melt cover for aluminum and magnesium alloys |
-
2005
- 2005-10-04 US US11/244,117 patent/US7393862B2/en not_active Expired - Lifetime
-
2006
- 2006-03-10 UA UAA200805327A patent/UA94062C2/ru unknown
- 2006-10-03 EP EP12171482A patent/EP2526946A1/en not_active Withdrawn
- 2006-10-03 KR KR1020147014746A patent/KR20140082857A/ko not_active Application Discontinuation
- 2006-10-03 WO PCT/US2006/038844 patent/WO2007041637A2/en active Application Filing
- 2006-10-03 AU AU2006299431A patent/AU2006299431B2/en active Active
- 2006-10-03 PE PE2006001200A patent/PE20070761A1/es not_active Application Discontinuation
- 2006-10-03 CN CN2013100490881A patent/CN103142594A/zh active Pending
- 2006-10-03 EP EP06816250A patent/EP1931343A2/en not_active Ceased
- 2006-10-03 KR KR1020087010897A patent/KR20080058469A/ko active Application Filing
- 2006-10-03 KR KR1020167023898A patent/KR20160105940A/ko not_active Application Discontinuation
- 2006-10-03 CN CNA2006800441296A patent/CN101316588A/zh active Pending
- 2006-10-03 JP JP2008534665A patent/JP5916977B2/ja active Active
- 2006-10-03 CA CA002570755A patent/CA2570755A1/en not_active Abandoned
- 2006-10-03 BR BRPI0616670-9A patent/BRPI0616670A2/pt not_active Application Discontinuation
- 2006-10-03 CA CA2972299A patent/CA2972299A1/en not_active Abandoned
- 2006-10-03 RU RU2008117432/15A patent/RU2406501C2/ru not_active IP Right Cessation
- 2006-10-03 NZ NZ567049A patent/NZ567049A/en unknown
- 2006-10-03 AR ARP060104355A patent/AR057868A1/es unknown
- 2006-10-04 TW TW095136901A patent/TWI415610B/zh active
-
2008
- 2008-02-19 US US12/070,451 patent/US8440194B2/en active Active
- 2008-03-25 IL IL190437A patent/IL190437A/en active IP Right Grant
- 2008-04-30 NO NO20082068A patent/NO20082068L/no not_active Application Discontinuation
- 2008-10-03 ZA ZA200803700A patent/ZA200803700B/xx unknown
-
2010
- 2010-09-07 RU RU2010137395/15A patent/RU2010137395A/ru unknown
-
2011
- 2011-12-02 US US13/310,543 patent/US8632787B2/en not_active Expired - Lifetime
-
2013
- 2013-01-16 JP JP2013005399A patent/JP2013091659A/ja active Pending
- 2013-05-08 US US13/889,473 patent/US8623384B2/en not_active Expired - Lifetime
- 2013-12-31 US US14/145,171 patent/US9056103B2/en not_active Expired - Lifetime
-
2014
- 2014-09-17 JP JP2014188693A patent/JP2015044811A/ja active Pending
-
2015
- 2015-06-03 US US14/729,934 patent/US9498472B2/en not_active Expired - Lifetime
-
2016
- 2016-10-17 US US15/295,910 patent/US20170095464A1/en not_active Abandoned
-
2017
- 2017-07-13 JP JP2017136968A patent/JP2017222686A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009510171A5 (US20070167479A1-20070719-C00034.png) | ||
| RU2008117432A (ru) | Способы применения 3-(4-амино-1-оксо-1,3-дигидроизоиндол-2-ил)пиперидин-2,6-диона для лечения определенных типов лейкоза | |
| JP2009545600A5 (US20070167479A1-20070719-C00034.png) | ||
| Blower et al. | Drug–drug interactions in oncology: why are they important and can they be minimized? | |
| Kelland | Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status | |
| JP2005530784A5 (US20070167479A1-20070719-C00034.png) | ||
| RU2407532C9 (ru) | Комбинации, предназначенные для лечения заболеваний, включающих пролиферацию клеток | |
| RU2009107535A (ru) | Применение 3-(4-амино-1-оксо-1,3-дигидроизоиндол-2-ил)пиперидин-2,6-диона для лечения лимфом из клеток мантийной зоны | |
| JP2009517403A5 (US20070167479A1-20070719-C00034.png) | ||
| US20060281769A1 (en) | Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators | |
| US20060281771A1 (en) | Synergistic modulation of flt3 kinase using aminoquinoline and aminoquinazoline kinase modulators | |
| JP2009545601A5 (US20070167479A1-20070719-C00034.png) | ||
| US20060281700A1 (en) | Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators | |
| ATE350040T1 (de) | Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin | |
| JP2014040437A5 (US20070167479A1-20070719-C00034.png) | ||
| JP2008533142A (ja) | α７ニューロンニコチン性受容体リガンドおよび抗精神病薬組成物 | |
| US20060281755A1 (en) | Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators | |
| JP2008514577A5 (US20070167479A1-20070719-C00034.png) | ||
| IL178745A (en) | Use of 4- (amino) -2 (2, 6-dioxo (3-piperidyl)) -isoindoline -1, 3-discussion of preparation of a medical vaccine for the treatment of myeloma | |
| JP2006526644A5 (US20070167479A1-20070719-C00034.png) | ||
| JP2019516733A5 (US20070167479A1-20070719-C00034.png) | ||
| JP2006514611A5 (US20070167479A1-20070719-C00034.png) | ||
| EA200701681A1 (ru) | Пероральная лекарственная форма, содержащая росиглитазон | |
| JP2011500805A5 (US20070167479A1-20070719-C00034.png) | ||
| US20070004660A1 (en) | Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines |
